HealthEdge Announces Successful Sale of LifeSync to Amphenol

Rhea-AI Summary

HealthEdge Investment Partners has completed the sale of LifeSync to Amphenol (NYSE: APH). LifeSync, a developer and manufacturer of patient monitoring devices, has shown remarkable growth under HealthEdge's ownership, increasing revenues from $5 million to approximately $100 million.

During HealthEdge's ownership, the company implemented several strategic initiatives, including: appointing new management, completing four acquisitions for complementary products and manufacturing integration, and reorganizing into neuro, cardio, and contract manufacturing divisions. LifeSync's products have impacted millions of patients in hospitals and high acuity settings.

Positive

• Revenue growth from $5M to $100M under HealthEdge ownership
• Successful completion of four strategic acquisitions
• Vertical integration of manufacturing operations
• Established three specialized divisions (neuro, cardio, contract manufacturing)

Negative

• None.

News Market Reaction

+0.22%

1 alert

+0.22% News Effect

On the day this news was published, APH gained 0.22%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

TAMPA, Fla. and CORAL SPRINGS, Fla., Feb. 18, 2025 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge"), a lower middle market private equity fund focused on healthcare, announced today that it has completed the sale of LifeSync ("LifeSync" or the "Company"), a developer, manufacturer, and marketer of disposable and reusable patient monitoring devices and connections sold to hospitals and other high acuity settings. LifeSync was acquired by Amphenol (NYSE: APH), one of the world's largest providers of connectors, interconnect systems, antennas, sensors and specialty cable.

"When we first invested in LifeSync, our objective was to grow revenues and scale an entrepreneurial business with a great product and unique IP," said Brian Anderson, Managing Partner of HealthEdge. "We accomplished our goals and more by appointing a new management team, completing four acquisitions that added complementary products and vertically integrated manufacturing, and reorganizing the company into its neuro, cardio, and contract manufacturing divisions. In the process, LifeSync touched millions of patients with its products, and grew revenues from $5 million to approximately $100 million. Given the strong organic and acquisitive growth of the Company, this exit yielded strong investment returns for HealthEdge Fund II."

"I am proud of the growth LifeSync has accomplished and the work our global team does each day to provide critical medical products to hospitals," added Bob Buehler, General Manager of LifeSync. "HealthEdge has been an invaluable partner to LifeSync as the Company has evolved during my tenure as CEO. We are excited to join Amphenol and work on the Company's future growth plans."

Hill Ward Henderson acted as legal counsel and Lincoln International LLC served as financial advisor to LifeSync on the sale.

ABOUT HEALTHEDGE

HealthEdge Investment Partners, LLC is an operating-oriented private equity firm founded in 2005 that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge's partners have more than 100 years of combined experience in healthcare as operators and investors. For more information on HealthEdge, please visit www.healthedgepartners.com.

ABOUT LIFESYNC

LifeSync is the only vertically integrated company focused solely on patient connections, providing cardiac cables, leadwires and neuromonitoring connections in addition to contract manufacturing solutions. Headquartered in Coral Springs, FL, LifeSync develops and manufactures products at its state-of-the-art manufacturing capabilities.

ABOUT AMPHENOL

Amphenol Corporation is one of the world's largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable.  Amphenol designs, manufactures and assembles its products at facilities in approximately 40 countries around the world and sells its products through its own global sales force, independent representatives and a global network of electronics distributors.  Amphenol has a diversified presence as a leader in high-growth areas of the interconnect market including: Automotive, Commercial Aerospace, Communications Networks, Defense, Industrial, Information Technology and Data Communications and Mobile Devices. For more information, visit www.amphenol.com.

CONTACT:
HealthEdge Investment Partners, LLC
5550 W. Executive Drive, Suite 230
Tampa, Florida 33609
(813) 490-7100
www.healthedgepartners.com

View original content:https://www.prnewswire.com/news-releases/healthedge-announces-successful-sale-of-lifesync-to-amphenol-302378866.html

SOURCE HealthEdge Investment Partners, LLC

FAQ

How much did LifeSync's revenue grow before being acquired by Amphenol (APH)?

LifeSync's revenue grew from $5 million to approximately $100 million under HealthEdge's ownership before being acquired by Amphenol.

What strategic changes did LifeSync implement before the APH acquisition?

LifeSync appointed new management, completed four acquisitions for complementary products, integrated manufacturing vertically, and reorganized into three divisions: neuro, cardio, and contract manufacturing.

What are LifeSync's main product divisions after the Amphenol (APH) acquisition?

LifeSync operates through three main divisions: neuro, cardio, and contract manufacturing.

What type of medical products does LifeSync bring to Amphenol's (APH) portfolio?

LifeSync brings disposable and reusable patient monitoring devices and connections used in hospitals and high acuity settings to Amphenol's portfolio.